Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer

被引：0
|
作者：
Sung Gwe Ahn
Yoon Jin Cha
Soon June Bae
Chanik Yoon
Hak Woo Lee
Joon Jeong
机构：
[1] Yonsei University College of Medicine,Department of Surgery, Gangnam Severance Hospital
[2] Yonsei University College of Medicine,Department of Pathology, Gangnam Severance Hospital
来源：
BMC Cancer | / 18卷
关键词：
Tumor-infiltrating lymphocytes; 21-gene recurrence score; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Claudette E. Loo
    Lisanne S. Rigter
    Kenneth E. Pengel
    Jelle Wesseling
    Sjoerd Rodenhuis
    Marie-Jeanne T. F. D. Vrancken Peeters
    Karolina Sikorska
    Kenneth G. A. Gilhuijs
    Breast Cancer Research, 18
  • [42] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [43] Diversity of ER-positive and HER2-negative breast cancer stem cells attained using selective culture techniques
    Sueoka, Satoshi
    Kai, Azusa
    Kobayashi, Yukino
    Ito, Masaoki
    Sasada, Shinsuke
    Emi, Akiko
    Gotoh, Noriko
    Arihiro, Koji
    Nakayama, Koh
    Okada, Morihito
    Kadoya, Takayuki
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [44] Altona Prognostic Index: A New Prognostic Index for ER-Positive and Her2-Negative Breast Cancer of No Special Type
    Wegscheider, Anne-Sophie
    Ulm, Bernhard
    Friedrichs, Kay
    Lindner, Christoph
    Niendorf, Axel
    CANCERS, 2021, 13 (15)
  • [45] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
    C. Criscitiello
    A. Vingiani
    P. Maisonneuve
    G. Viale
    G. Viale
    G. Curigliano
    Breast Cancer Research and Treatment, 2020, 183 : 347 - 354
  • [46] FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
    Koolen, Bas B.
    Pengel, Kenneth E.
    Wesseling, Jelle
    Vogel, Wouter V.
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Vincent, Andrew D.
    Gilhuijs, Kenneth G. A.
    Rodenhuis, Sjoerd
    Rutgers, Emiel J. Th.
    Olmos, Renato A. Valdes
    BREAST, 2013, 22 (05) : 691 - 697
  • [47] Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
    Bischoff, Herve
    Espie, Marc
    Petit, Thierry
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, : 1210 - 1224
  • [48] Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
    Hiroji Iwata
    Norikazu Masuda
    Yutaka Yamamoto
    Tomomi Fujisawa
    Tatsuya Toyama
    Masahiro Kashiwaba
    Shoichiro Ohtani
    Naruto Taira
    Takehiko Sakai
    Yoshie Hasegawa
    Rikiya Nakamura
    Hiromitsu Akabane
    Yukiko Shibahara
    Hironobu Sasano
    Takuhiro Yamaguchi
    Kentaro Sakamaki
    Helen Bailey
    Diana B. Cherbavaz
    Debbie M. Jakubowski
    Naoko Sugiyama
    Calvin Chao
    Yasuo Ohashi
    Breast Cancer Research and Treatment, 2019, 173 : 123 - 133
  • [49] Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
    Luque, Melani
    Sanz-Alvarez, Marta
    Morales-Gallego, Miriam
    Madoz-Gurpide, Juan
    Zazo, Sandra
    Dominguez, Carolina
    Cazorla, Alicia
    Izarzugaza, Yann
    Arranz, Juan Luis
    Cristobal, Ion
    Rojo, Federico
    CANCERS, 2022, 14 (24)
  • [50] Development of recurrence risk score using 95-gene classifier and its application to formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative and node-negative breast cancer
    Naoi, Yasuto
    Saito, Yuria
    Kishi, Kazuki
    Shimoda, Masafumi
    Kagara, Naofumi
    Miyake, Tomohiro
    Tanei, Tomonori
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    ONCOLOGY REPORTS, 2019, 42 (06) : 2680 - 2685
12345